One of the most controversial topics in Nephrology is how best to manage cardiovascular risk factors in CKD and ESRD patients. Should cholesterol and LDL levels be lowered to levels that have been proven to improve survival in non-CKD and non-ESRD patients? This teaching resource reviews three landmark clinical trials that focus on this issue and have impacted our understanding of atherosclerotic disease in CKD and ESRD patients.

***Note: Comments about this teaching resource, its content, and your thoughts can be made on this website (by registered users) or on Facebook (all users).

**************************************
Time Required (estimated): 60 minutes
Title: Lipid Lowering Therapy in CKD and ESRD – A review of the 4D, AURORA, and SHARP Trials
Author: Sarath Kolluru, MD1 and Tejas Desai, MD2
Author Type: 1Fellow; 2Faculty
Citation: Nephrology On-Demand 2011
Date Created: 2011
Revisions: 2011 x 5
Disclaimers: None Indicated
Resource Type: Video
Recommend to a Colleague/Friend
**************************************

LEARNING OPTIONS:

To view the interactive video, click here
To view this video using an iPad or iPhone, see below
To test your knowledge in this subject, click here




Transparent Peer Review
Your reviews are anonymous

GD Star Rating
loading...

To learn more about our 6-point transparent peer review system, click here



Lipid Lowering Therapy in CKD and ESRD – A review of the 4D, AURORA, and SHARP Trials, 9.2 out of 10 based on 2 ratings
Share

Comments

More in CKD, End-Stage Renal Disease, General Nephrology (88 of 244 articles)


One of the most controversial topics in Nephrology is how ...